Abstract: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

Abstract: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

Abstract: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

Abstract: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

Abstract: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

Abstract: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

Abstract: A therapeutic compound comprises a KGD-containing peptide, tandem repeats thereof, combinations thereof, or combinations thereof with an RGD-containing peptide or tandem repeats thereof, or peptide analogues or non-peptide organic analogues of the RGD and KGD tripeptides, and a pharmaceutical agent. A therapeutic composition comprises the compound of this invention and a pharmaceutically acceptable carrier. A polydeoxyribonucleotide comprises a DNA sequence, and a polyribonucleotide comprises an RNA sequence, encoding the compound of the invention, where the pharmaceutical agent is a peptide. A self-replicating DNA carries the polydeoxyribonucleotide described above and a transformed host cell comprises the self-replicating DNA. Therapeutic platelets are loaded with a therapeutic compound comprising a peptide comprising RGD or KGD, peptide analogues or organic analogues thereof, tandem repeats thereof, or combinations thereof, and a pharmaceutical agent operatively linked to the peptide.

Abstract: Methods for detecting fibrin or fibrin clots in a host suspected of producing fibrin by: introducing labeled tissue plasminogen activator or a binding site fragment derived therefrom into the host's bloodstream and assaying for the presence of concentrations of labeled tissue plasminogen activator in said host. Also provided are kits for practicing the invention.